Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine

Journal of the National Cancer Institute

Volumn 93, Issue 6, 2001, Pages 427-436

  Hemstreet III, George P ^a   Yin, Songnian ^c   Ma, Zhenzhong ^d   Bonner, Rebecca Bass ^a   Bi, Wenfang ^c   Rao, Jian Y ^e   Zang, Meifu ^f   Zheng, Qinlong ^a   Bane, Barbara ^a   Asal, Nabih ^g   Li, Guilan ^c   Feng, Peiwen ^h   Hurst, Robert E ^a   Wang, Wenyu ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d BEIJING HOSPITAL   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PEKING UNION MEDICAL COLLEGE   (China)

^g MOREHOUSE SCHOOL OF MEDICINE   (United States)

^h Institute of Occupational Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIDINE; BIOLOGICAL MARKER; CELL DNA; CYTOSKELETON PROTEIN; G ACTIN; PROTEIN P300;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHINESE; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; URINALYSIS; UROTHELIUM; WORKER;

EID: 0035925570     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.6.427     Document Type: Article

References (56)

1. Bladder cancer screening among primary aluminum production workers in Quebec
2. Bladder cancer in workers of the dyeing industry
3. Screening workers exposed to 4,4′-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy
4. Bladder cancer screening in the United Kingdom
5. Genetic instability and tumor cell variation
6. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis
7. Estimates of the worldwide incidence of eighteen major cancers in 1985
8. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden
9. Bladder cancer in the aluminum industry
10. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff Intermediates in the British chemical industry
11. Mortality and incidence of bladder cancer in benzidine-exposed workers in China
12. Role of medical screening in the prevention of occupational disease
13. DNA hyperploidy as a marker for biological response to bladder carcinogen exposure
14. Brief report: Molecular biology and the early detection of carcinoma of the bladder - The case of Hubert H. Humphrey
15. Validation of intermediate end points in cancer research
16. Recent progress in the interpretation of malignancy associated changes (MAC)
17. Cytology of bladder cancer
18. Selection and development of biomarkers for bladder cancer
19. Field molecular epidemiology. Feasibility of monitoring for the malignant bladder cell phenotype in a benzidine-exposed occupational cohort
20. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells
21. Instrumentation, accuracy and quality control in development of quantitative fluorescence image analysis
22. American Joint Committee on Cancer (AJCC). Urinary bladder
23. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide
24. Quantitative fluorescence measurements of AO-stained normal and malignant bladder cells
25. The influence of malignant cell cytology screening on the survival of industrial bladder cancer cases
26. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials
27. Cancer statistics, 1999
28. Screening, early detection, and prevention of bladder cancer
29. Methodological issues in the use of biological markers in cancer epidemiology: Cohort studies
30. Sources of variation in biomarkers
31. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: Quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers
32. Common patterns of genetic evolution in human solid tumors
33. Quantitative fluorescence image analysis in bladder cancer screening
34. Cancer detection by quantitative fluorescence image analysis
35. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies
36. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer
37. Neural net-based identification of cells expressing the p300 tumor-related antigen using fluorescence image analysis
38. Cellular F-actin levels as a marker for cellular transformation: Correlation with bladder cancer risk
39. Abnormal G-actin content in single prostate cells as a biomarker for prostate cancer
40. Bias and confounding in molecular epidemiological studies: Special considerations
41. Amplification at chromosome 11q13 in transitional cell tumours of the bladder
42. Mutations of mitotic checkpoint genes in human cancers
43. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
44. Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer
45. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine
46. Telomerase activity: A potential marker of bladder transitional cell carcinoma in bladder washes
47. Cytokeratin 20: A new marker for early detection of bladder cell carcinoma?
48. Molecular pathology and biomarkers of bladder cancer
49. Alterations of the actin polymerization status as an apoptotic morphological effector in HL-60 cells
50. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder
51. Cancer statistics, 2000
52. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker
53. Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer - Screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group
54. Improved detection of recurrent bladder cancer using the Bard BTA stat Test